Monoferric (Ferric Derisomaltose)

Ferric derisomaltose is a stable iron-carbohydrate complex that, after IV infusion, is taken up by macrophages of the reticuloendothelial system. Inside the cells, the complex releases iron, which is then incorporated into hemoglobin and other iron‑dependent proteins, restoring normal iron stores and supporting red blood cell production.

The prescribed dose of Monoferric is individualized by the treating physician. Factors such as the patient’s total iron deficit, body weight, hemoglobin level, and underlying condition (e.g., chronic kidney disease) are evaluated to calculate the appropriate amount of elemental iron needed for safe and effective repletion.

The safety of Monoferric in pregnancy or while breastfeeding has not been definitively established. Healthcare providers should weigh the potential benefits against any unknown risks and consider alternative iron therapies when appropriate. Decisions are made on a case‑by‑case basis by the prescribing clinician.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity of Monoferric. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and import documentation.

Monoferric (ferric derisomaltose) delivers a high dose of elemental iron in a single infusion with a low risk of labile iron release, which can reduce oxidative stress compared with some older iron sucrose formulations. Its stability allows for faster administration and fewer infusion‑related reactions, making it a convenient option for many clinical settings.

Monoferric must be stored refrigerated between 2 °C and 8 °C. The solution should be kept in its original container, protected from light, and must not be frozen or shaken. Prior to use, inspect the vial for particulate matter or discoloration and allow it to reach room temperature if required by the administration protocol.

Monoferric is administered as an intravenous infusion by a qualified healthcare professional. The prescribed volume is diluted according to the product label, then infused over the recommended time period, typically ranging from 15 to 30 minutes, while monitoring the patient for any signs of adverse reactions.

The most serious risks include severe hypersensitivity reactions such as anaphylaxis, sudden hypotension during infusion, and iron overload if cumulative dosing exceeds recommended limits. Prompt recognition and immediate medical intervention are essential for managing these potentially life‑threatening events.

Monoferric is contraindicated in patients with known hypersensitivity to ferric derisomaltose or any component of the formulation, as well as in individuals with active systemic infections, severe hepatic impairment, or iron overload conditions such as hemochromatosis. Clinical judgment should also exclude use in patients with uncontrolled hypertension or severe cardiac disease.